Autolus Therapeutics plc (AUTL) Earnings Call Transcripts

Autolus Therapeutics plc's Latest Earnings Call - April 8, 2026

In the first quarter of fiscal year 2026, Autolus Therapeutics plc reported significant advancements in its ALL B-cell CAR T-cell therapy, AUCATZYL, particularly in treating adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). The company highlighted a 77% overall response rate and a promising safety profile, with a notable reduction in severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Management maintained a positive outlook for future growth, emphasizing the potential for AUCATZYL to become a frontline treatment option, which could significantly enhance patient outcomes and market penetration.

Reported metrics

Guidance from management

Management signaled a strong commitment to advancing AUCATZYL into frontline therapy, with ongoing studies expected to provide critical data for regulatory approval in 2027.

What management said

Thank you, Dr. Pulsipher, and thank you to all of our speakers. We are happy to take questions via the webcast platform. I have a few queued up here so we can jump right in. First is, any comments on other forms of toxicity in the ROCCA study. This may be important given older patients being treated.

Thanks a lot, Amanda. I think, Lori, that would be clearly one for you. Obviously, you're focused on particularly the immunological toxicities with CRS and ICANS. But clearly, these patients do experience our adverse events. I think it would be great to get a perspective.

What analysts pressed on

Analysts expressed concerns regarding the long-term efficacy and safety of AUCATZYL in diverse patient populations, particularly regarding the potential for relapse and the need for additional therapies post-treatment. Questions were raised about the comparative risks of CAR T therapy versus traditional transplant methods.

Main topics on the call

• Clinical Efficacy of AUCATZYL — Management reported a 77% overall response rate across all patients treated with AUCATZYL, with many achieving durable remissions lasting over three years. Dr. Park noted, "Majority of the responses were MRD-negative, me...
• Safety Profile Improvements — The safety profile of AUCATZYL was highlighted as a key advantage, with Dr. Motley stating, "The rates of CRS are approximately 50% in the real world... with no instances of higher-grade CRS." This positions AUCATZYL as ...
• Market Expansion Potential — Management expressed confidence in expanding AUCATZYL's use into frontline settings, with Dr. Jabbour stating, "We believe CAR-T can have... independent reaction can offer arenifor these patients at high risk." This sugg...
• Real-World Data Validation — The ROCCA consortium presented real-world data showing nearly 95% response rates and a 70% MRD-negative complete remission rate, which Dr. Motley described as "superior to what was seen in the trial." This reinforces the...

Read the full Autolus Therapeutics plc transcript (April 8, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 52 Autolus Therapeutics plc earnings call transcripts on record, spanning January 16, 2020 to August 11, 2026. Based on this history, Autolus Therapeutics plc reports quarterly. The most recent call on file is dated August 11, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

AUTL

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

52

First call

January 16, 2020

Most recent

August 11, 2026

Reporting cadence

quarterly